What Are the Most Powerful Immunogen Design Vaccine Strategies? (Q28729792)

Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren

page(s)

a029470

0 references

cites work

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Antibodies, viruses and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Influenza vaccine: the challenge of antigenic drift.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

In Vaccine Design, Looks Do Matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

The structural biology of type I viral membrane fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Highly Conserved Protective Epitopes on Influenza B Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

The burgeoning burden of respiratory syncytial virus among children

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Six decades of vaccine development--a personal history

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Live-attenuated respiratory syncytial virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Architecture of respiratory syncytial virus revealed by electron cryotomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Enhancing protein crystallization through precipitant synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Philosophy of science. The coordinates of truth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Structure and immune recognition of trimeric pre-fusion HIV-1 Env.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Identification of antigen-specific B cell receptor sequences using public repertoire analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Erratum: Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A029470

Recent zoonoses caused by influenza A viruses.

21 January 2018

1 reference

12 December 2020

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

1 reference

12 December 2020

Antibody neutralization and escape by HIV-1

1 reference

12 December 2020

Evolution and ecology of influenza A viruses

1 reference

12 December 2020

Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.

1 reference

12 December 2020